Leerink analyst Danielle Antalffy notes that both Edwards Lifesciences (EW) and Medtronic (MDT) traded down in reaction to a presentation of the German Aortic Valve Registry data in intermediate risk patients. However, she believes the selloff is overdone, with no change to her estimated total addressable transcatheter aortic valve replacement, or TAVR, market opportunity as there are key baseline characteristic differences between both the surgical valve and TAVR groups that skews the data, and randomized controlled clinical trial data trumps registry data.

11/14/16

EVER

11/14/16NO CHANGEEVER

Medtronic, Edwards Lifesciences defended at Evercore ISI

11/14/16

PIPR

11/14/16NO CHANGEPIPROverweight

Piper would buy TAVR names on 'GARY' registry weakness

Piper Jaffray analyst Brooks West attributes today's weakness in transcatheter aortic valve replacement makers Medtronic (MDT), Edwards Lifesciences (EW) and Boston Scientific (BSX) to a presentation at the AHA meeting of data from the German Aortic Valve Registry, or "GARY," comparing one year outcomes for patients at intermediate surgical risk who underwent isolated interventional versus conventional surgical aortic valve replacement for severe symptomatic aortic valve stenosis. The data showed a surprisingly negative result, but prior debates around the "GARY" led to no impact on TAVR volumes and West is "skeptical of the results," he tells investors. The firm has Overweight ratings on all three stocks mentioned above.

11/02/16

BMOC

11/02/16NO CHANGEBMOC

Dexcom still has positive catalysts, says BMO Capital

After Dexcom reported higher than expected Q3 revenue but said it does not expect its 2016 revenue to come in above its previous guidance range, BMO Capital analyst Joanne Wuensch says that the company's Q4 and 2017 results will probably be negatively impacted by Medtronic's (MDT) upcoming MiniMed 670G product. Nonetheless, the analyst says that the pending non-adjunctive label for Dexcom's CGM "can make waves," while it has "ample" room for growth in its "vastly underserved" market, as its "technology is nowhere near its full potential." The analyst cut her price target on the shares to $90 from $112 but keeps an Outperform rating on the stock.

Cleveland Research said Dollar General's Q3 are likely trending below consensus driven by continued competitive headwinds. The firm's analyst said Dollar General appears to ramping up promotional/price aggressiveness in order to drive a recovery and sees risk to near-term margin and sales consensus expectations.

09/23/16

09/23/16INITIATION

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

10/12/16

KEYB

10/12/16INITIATIONKEYBSector Weight

Dollar General initiated with a Sector Weight at KeyBanc

KeyBanc analyst Bradley Thomas initiated Dollar General with a Sector Weight saying consensus estimates still need to move down and looks to get more positive on further shares weakness.

10/13/16

10/13/16INITIATION

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aaron's (AAN) initiated with a Buy at Jefferies. 2. eBay (EBAY) and Etsy (ETSY) coverage assumed with a Neutral at Wedbush. 3. Five Below (FIVE) and Dollar Tree (DLTR) were initiated with an Overweight at KeyBanc while the firm initiated Dollar General (DG) with a Sector Weight. 4. Baxter (BAX) initiated with an Outperform at Wells Fargo. 5. Symantec (SYMC) initiated with an Outperform at FBN Securities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

CLFCliffs Natural

10/07/16

FBCO

10/07/16INITIATIONTarget $2FBCOUnderperform

Cliffs Natural reinstated with an Underperform at Credit Suisse

Credit Suisse analyst Curt Woodworth reinstated Cliffs Natural with an Underperform and a $2 price target primarily due to a bearish view on iron ore.

07/12/16

JPMS

07/12/16NO CHANGETarget $10.5JPMSOverweight

Cliffs Natural price target raised to $10.50 from $7 at JPMorgan

JPMorgan analyst Michael Gambardella raised his price target for Cliffs Natural Resources to $10.50 and keeps an Overweight rating on the name. The recent bankruptcy of Essar Steel Minnesota has further solidified Cliffs' "defensible business model," Gambardella tells investors in a research note. The short interest in the name, at 43% of outstanding float, is "extremely high despite the wave of positive developments," the analyst contends. He sees a likely positive catalyst from near-term earnings beats amid higher steel pricing.

Morgan Stanley analyst Evan Kurtz upgraded Cliffs Natural to Equal Weight and raised its price target to $9 from $3. The analyst believes the Trump victory has led to the first "credible long-term investment case" for steel equities for the first time in a decade and expects Trump's proposals for infrastructure spending and trade protection to add to demand and curb import supply. Kurtz said Cliffs is leveraged to HRC steel prices ad will benefit from higher blast furnace operating rates.

MKM Partners analyst Ian Ing raised his price target for NVIDIA (NVDA) to $106 from $87, saying that thematic attention is heating up as large suppliers are crowding into artificial intelligence as an investment theme with non-GPU solutions. While other suppliers may be able to come up with better performance-for-power in certain use cases, he believes NVIDIA GPUs still have user stickiness with developer incumbency and easy-to-use tools that will be difficult to overcome. The analyst also raised his price target for AMD (AMD) to $10.50 from $8 to reflect improved prospects for the company driven by new product pipeline. Although Ian expects AMD to be a relatively minor player, its shares are helped by continued A.I. headlines and NVIDIA, Intel (INTC), and Qualcomm (QCOM) turning increasingly vocal on the opportunity. He reiterates a Buy rating on NVIDIA and AMD shares.

Pacific Crest notes that Intel (INTC) said its PC customers are poised to reduce their inventories in Q4. The firm says that the comment is negative for Marvell (MRVL). However, the firm believes that Advanced Micro Devices (AMD), NVIDIA (NVDA), ON Semiconductor (ON) and Synaptics (SYNA) are "most resilient" to this development, given their share gains, growth and other factors.

Pacific Crest says that Intel's (INTC) data center results and commentary were "modestly disappointing," as enterprise demand for the company's data center products was "weak," according to the firm. The firm thinks that the negative enterprise results are "modestly negative for stocks with enterprise exposure, including Micron (MU), Seagate (STX) and Western Digital (WDC)."

10/19/16

ROTH

10/19/16NO CHANGETarget $40ROTHBuy

Roth Capital cuts Intel price target after guidance disappoints

Roth Capital analyst Suji Desilva lowered his price target for Intel to $40 from $43 after disappointing guidance. However, the analyst expects the shares to recover with a reset of expectations. Desilva continues to be encouraged by the company's transition to growth areas such as cloud data center, networking and IoT, and by the stable margin profile. He reiterates a Buy rating on the shares.

METMetLife

10/07/16

FBCO

10/07/16INITIATIONTarget $51FBCONeutral

MetLife initiated with a Neutral at Credit Suisse

Credit Suisse analyst John Nadel initiated MetLife with a Neutral and a $51 price target.

07/13/16

07/13/16DOWNGRADE

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Yelp (YELP) downgraded to Underperform from Market Perform at Wells Fargo with analyst Peter Stabler saying consensus expectations "embed too much optimism" for 2017 and 2018. 2. Starbucks (SBUX) downgraded to Mixed from Positive at OTR Global with the firm citing manager checks that indicate weaker-than-expected food and Frappuccino sales, impact from poor weather, and cannibalization. 3. SQM (SQM) downgraded to Sell from Neutral at Citi analyst Juan Tavarez saying the risk/reward is unfavorable with the stock up 42% year-to-date. 4. Robert Half (RHI) downgraded to Neutral from Buy at BofA/Merrill with the firm citing expectations of weaker fundamentals, FX headwinds, and increased concerns around the timing of the cycle. 5. MetLife (MET) downgraded to Hold from Buy at Deutsche Bank with analyst Yaron Kinar saying balance sheet risk is enhanced ahead of the company's separation and in light of low yields. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

09/22/16

WELS

09/22/16INITIATIONWELSOutperform

MetLife coverage resumed with an Outperform at Wells Fargo

09/23/16

WELS

09/23/16INITIATIONWELSOutperform

MetLife coverage resumed at Wells Fargo

As noted earlier, Wells Fargo resumed coverage of MetLife with an Outperform rating. The firm says that , in the wake of the company's decision to separate its retail business, it "should be less impacted by equity market movement and interest rates." As a result, the firm thinks that the stock's multiple should rise, while the company should require less capital, enabling it to buy back its shares. Wells set a $51-$53 price target on the stock.

USOUnited States Oil Fund

AMZNAmazon.com

$780.00

19.84 (2.61%)

11/17/16

PIPR

11/17/16NO CHANGEPIPR

Piper sees Trump-related Internet selloff as 'rare opportunity'

Piper Jaffray analyst Gene Munster says he would be "buying the fear" priced into Internet mega-caps. Concerns of President-Elect Trump's impact on tech companies are being largely extrapolated from sound bites that are unlikely to manifest during Trump's presidency, Munster tells investors in a research note. The selloff in "best-in-class" large cap internet stocks Apple (AAPL), Amazon.com (AMZN), Alphabet (GOOG), Facebook (FB) and Netflix (NFLX) presents a "rare opportunity," Munster writes. He believes Trump's threats towards Amazon are without merit and that net neutrality is unlikely to be reversed. He finds the valuations for each of the mega-caps "very attractive."

11/21/16

SBSH

11/21/16NO CHANGETarget $16SBSHBuy

Citi fields Pandora questions after Amazon on-demand launch

Citi analyst Mark Kelley says he's received a lot of questions from investors over the last few days on the impact from potentially lower prices for Pandora's (P) on-demand offering after Amazon (AMZN) launched a competing service. Amazon's on-demand offering costs $7.99 per month for Prime users, or $3.99 if you only want to listen on your echo device. Non-Prime users must pay $9.99 per month. The launch by Amazon has caused some speculation in the press that Apple (AAPL) is going to lower its prices, Kelley tells investors in a research note. The analyst does not expect Pandora to lower the price of on-demand to $7.99 per month. Kelley still believes on-demand music is the way the industry moves forward and he remains bullish on Pandora's long-term opportunity. The analyst has a Buy rating on the shares with a $16 price target.

11/21/16

BARD

11/21/16NO CHANGEBARDOutperform

Baird expects Amazon.com distribution announcement with Patterson

Following industry conversions, Baird analyst Jeff Johnson expects Patterson Companies (PDCO) to announce an Amazon.com (AMZN) distribution agreement tomorrow. What the analyst hadnt considered and is now hearing is that Amazon could fulfill orders placed through Patterson's order portal, lowering Patterson's fulfillment costs and given the company breathing room as it pursues DSO deals. Johnson rates Patterson a Neutral with a $48 price target.

11/18/16

OPCO

11/18/16NO CHANGEOPCO

Public cloud infrastructure market will be $62B by 2020, says Oppenheimer

Oppenheimer analyst Timothy Horan says "the race is on" for public cloud providers to get as much of their customers' data on their respective cloud platforms as possible. The analyst believes Amazon (AMZN) Web Services, Microsoft (MSFT), and Alphabet's Google (GOOG; GOOGL) have ambitions to become the dominant OS of the cloud, and to do so these companies will aim to have integrated solutions from the infrastructure layer to services through first-party offerings and/or the development of a strong partner channel. He views AWS as the primary wholesale cloud platform and Microsoft as the enterprise platform. However, given the relative immaturity of the market and the massive $1T opportunity, all three have been successful focusing on multiple segments, Horan adds, noting that he expects the public cloud infrastructure market to be $62B by 2020.

CELGCelgene

$124.16

2.19 (1.80%)

11/08/16

11/08/16INITIATION

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Adient (ADNT) initiated with a Neutral at JPMorgan. 2. JinkoSolar (JKS) initiated with a Buy at Craig-Hallum. 3. Amgen (AMGN), Gilead (GILD), and Celgene (CELG) initiated with a Buy at Mizuho while the firm initiated Biogen (BIIB) with a Neutral. 4. BioScrip (BIOS) resumed with a Buy at Jefferies. 5. SQM (SQM) initiated with a Market Perform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

RBC Capital recommends buying biotech stocks today on weakness. The firm notes that stocks usually rebound after they drop due to political events that don't affect their fundamentals, and it believes that the decline in biotech stocks today is in that category. The firm says that President-elect Trump probably won't focus on drug prices or Medicare reform. It adds that biotech companies should benefit from the fact that Congress will stay in GOP hands and the apparent failure of California's Proposition 61 initiative. The firm identifies Celgene (CELG), Biogen (BIIB), Vertex (VRTX), BioMarin (BMRN), and Prothena (PRTA) as its favorite names in the sector.

11/09/16

STPT

11/09/16DOWNGRADESTPTHold

Celgene downgraded to Hold from Buy at Standpoint Research

11/09/16

PIPR

11/09/16NO CHANGEPIPR

Piper sees improving environment for Biopharma M&A

The biotech sector is seeing a "massive relief rally" given the "surprise trifecta" of a Republican sweep, the voting down of Prop 61 in California and U.S. dollar weakness, Piper Jaffray analyst Joshua Schimmer tells investors in a research note. The door is now open to discuss potential repatriation of cash outside the U.S., which could be a green light on mergers and acquisitions, the analyst adds. He points out that Amgen (AMGN) and Gilead (GILD) hold the most overseas cash, with Celgene (CELG) and Biogen (BIIB) holding several billion as well. Schimmer believes the broader environment may be improving for M&A. He cautions, though, that the election of Trump does not remove the "major drug pricing overhang question."

JPMJPMorgan

11/09/16

11/09/16DOWNGRADE

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. JPMorgan (JPM) downgraded to Neutral from Outperform at Baird with analyst David George noting the stock's outperformance and the higher re-rating of its valuation multiple. 2. GoPro (GPRO) downgraded to Neutral from Outperform at Wedbush, to Market Perform from Outperform at Raymond James, and to Sell from Neutral at Dougherty. 3. Universal Health (UHS) downgraded to Neutral from Buy at BofA/Merrill, to Neutral from Buy at Mizuho, and to Market Perform from Outperform at Avondale. 4. Globus Medical (GMED) downgraded to Market Perform from Outperform at JMP Securities, to Perform from Outperform at Oppenheimer, and to Market Perform from Outperform at William Blair. 5. Delphi (DLPH) and Magna (MGA) were downgraded to Underperform from Buy at BofA/Merrill while the firm downgraded Lear (LEA), American Axle (AXL), Adient (ADNT), and BorgWarner (BWA) to Underperform from Neutral. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

11/11/16

RBCM

11/11/16NO CHANGERBCM

Banks to benefit from higher interest rates, says RBC Capital

RBC Capital believes that the Fed is committed to raising interest rates, and it expects FOMC members' forecast to show they expect two rate increases to occur in 2017. The firm expects higher rates to boost banks' net interest margin, raising their profits. It identifies Bank of America (BAC), JPMorgan (JPM), Citizens Financial (CFG),M&T Bank (MTB), and Regions Financial (RF) as being among the banks most likely to benefit from short-term rate increases.

11/18/16

11/18/16INITIATIONTarget $65Underweight

American Express initiated with an Underweight at Stephens

As previously reported, Stephens analyst started American Express (AXP) with an Underweight rating and $65 price target, citing rising rates, shrinking markets as American Express ramps up rewards to maintain share, and the risk to 2017 EPS guidance. The analyst expects competition from bank peers, such as JPMorgan (JPM) and Citi (C), to continue to pressure American Express' earnings.

11/09/16

BARD

11/09/16DOWNGRADETarget $72BARDNeutral

JPMorgan downgraded to Neutral at Baird

As reported previously, Baird analyst David George downgraded JPMorgan to Neutral from Outperform. The analyst noted its outperformance and the higher re-rating of its valuation multiple. George believes investors should reduce their risk heading into a potential interest rate hike. He maintained his $72 price target on JPMorgan shares.

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Chesapeake Utilities (CPK) initiated with a Neutral at Ladenburg. 2. CONSOL (CNX) initiated with a Neutral at Goldman. 3. Johnson Controls (JCI) assumed with an Equal Weight at Barclays. 4. American Midstream Partners (AMID) initiated with a Buy at Janney Capital. 5. Brookfield Infrastructure (BIP) coverage resumed with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Abercrombie & Fitch (ANF) downgraded to Sell from Hold at Argus with analysts John Eade and Katelyn Bayone citing the company's third quarter miss and what they see as its "challenging sales outlook for the remainder of the year." 2. Duluth Holdings (DLTH) downgraded to Hold from Buy at Stifel and to Market Perform from Outperform at William Blair. 3. DAVIDsTEA (DTEA) downgraded to Market Perform from Outperform at BMO Capital and to Market Perform from Outperform at William Blair. 4. Hilton (HLT) downgraded to Outperform from Buy at CLSA with analyst Jon Oh citing valuation. 5. Horizon Pharma (HZNP) downgraded to Neutral from Buy at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) upgraded to Outperform from Market Perform at Leerink with analyst Seamus Fernandez saying the recent weakness in shares provides an "excellent entry point" ahead of several critical pipeline events that have the potential "to transform this giant into an exciting growth story." 2. Autodesk (ADSK) upgraded to Buy from Hold at Canaccord with analyst Richard Davis citing expectations for improved free cash flow, as he sees a path to $6 in FCF by 2020 and $11 per share in 2022. 3. Eaton (ENT) upgraded to Overweight from Neutral at JPMorgan with analyst Ann Duignan saying optionality of the company's balance sheet should offset broad weakness across its end markets. 4. Fluor (FLR) upgraded to Buy from Neutral at Citi with analyst Andrew Kaplowitz saying the company is positioned to outperform given amid oil and gas capex stabilization, a lift off the bottom in mining off the bottom and "muted" 2017 expectations. 5. Sysco (SYY) upgraded to Neutral from Sell at Goldman. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.